Scott J - Search Results

1

Assessing and communicating heterogeneity of treatment effects for patient subpopulations: Panel discussion on considerations in design and analysis.

Rothmann M, Crown W, Louis TA, Permutt T, Ruberg S, Segal J, Scott J. Rothmann M, et al. Among authors: scott j. Pharm Stat. 2021 Sep;20(5):952-964. doi: 10.1002/pst.2077. Epub 2020 Oct 28. Pharm Stat. 2021. PMID: 33118319

2

BayesWeb: a user-friendly platform for exploratory Bayesian analysis of safety signals from small clinical trials.

Scott JA, Hand AL, Sian LS. Scott JA, et al. J Biopharm Stat. 2011 Sep;21(5):1030-41. doi: 10.1080/10543406.2011.590924. J Biopharm Stat. 2011. PMID: 21830929

3

Sample size estimation in single-arm clinical trials with multiple testing under frequentist and Bayesian approaches.

Zaslavsky BG, Scott J. Zaslavsky BG, et al. Among authors: scott j. J Biopharm Stat. 2012;22(4):819-35. doi: 10.1080/10543406.2012.676585. J Biopharm Stat. 2012. PMID: 22651117

4

Bayesian methods for design and analysis of safety trials.

Price KL, Xia HA, Lakshminarayanan M, Madigan D, Manner D, Scott J, Stamey JD, Thompson L. Price KL, et al. Among authors: scott j. Pharm Stat. 2014 Jan-Feb;13(1):13-24. doi: 10.1002/pst.1586. Epub 2013 Jul 30. Pharm Stat. 2014. PMID: 23897858

5

Addressing prior-data conflict with empirical meta-analytic-predictive priors in clinical studies with historical information.

Li JX, Chen WC, Scott JA. Li JX, et al. J Biopharm Stat. 2016;26(6):1056-1066. doi: 10.1080/10543406.2016.1226324. Epub 2016 Aug 19. J Biopharm Stat. 2016. PMID: 27541990

6

Conditional power in vaccine trials with seasonal variations.

Tang X, Yan LK, Scott JA. Tang X, et al. J Biopharm Stat. 2022 May 4;32(3):427-440. doi: 10.1080/10543406.2022.2065504. Epub 2022 Jun 29. J Biopharm Stat. 2022. PMID: 35767382

7

Bayesian Methods in Human Drug and Biological Products Development in CDER and CBER.

Ionan AC, Clark J, Travis J, Amatya A, Scott J, Smith JP, Chattopadhyay S, Salerno MJ, Rothmann M. Ionan AC, et al. Among authors: scott j. Ther Innov Regul Sci. 2023 May;57(3):436-444. doi: 10.1007/s43441-022-00483-0. Epub 2022 Dec 2. Ther Innov Regul Sci. 2023. PMID: 36459346 Free PMC article. Review.

8

Application of Bayesian methods to accelerate rare disease drug development: scopes and hurdles.

Kidwell KM, Roychoudhury S, Wendelberger B, Scott J, Moroz T, Yin S, Majumder M, Zhong J, Huml RA, Miller V. Kidwell KM, et al. Among authors: scott j. Orphanet J Rare Dis. 2022 May 7;17(1):186. doi: 10.1186/s13023-022-02342-5. Orphanet J Rare Dis. 2022. PMID: 35526036 Free PMC article. Review.

9

Missing data issues at the FDA Center for Biologics Evaluation and Research.

Scott JA, Hsu H. Scott JA, et al. J Biopharm Stat. 2011 Mar;21(2):196-201. doi: 10.1080/10543406.2011.550095. J Biopharm Stat. 2011. PMID: 21390996 Review.

10

CBER's Experience With Adaptive Design Clinical Trials.

Lin M, Lee S, Zhen B, Scott J, Horne A, Solomon G, Russek-Cohen E. Lin M, et al. Among authors: scott j. Ther Innov Regul Sci. 2016 Mar;50(2):195-203. doi: 10.1177/2168479015604181. Ther Innov Regul Sci. 2016. PMID: 30227002

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

10,495 results

Search Page